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Abstract
Background: Guidance is needed on best medical management for advanced HIV disease with multidrug resistance (MDR)
and limited retreatment options. We assessed two novel antiretroviral (ARV) treatment approaches in this setting.
Methods and Findings: We conducted a 262 factorial randomized open label controlled trial in patients with a CD4 count
#300 cells/ml who had ARV treatment (ART) failure requiring retreatment, to two options (a) re-treatment with either
standard (#4 ARVs) or intensive ($5 ARVs) ART and b) either treatment starting immediately or after a 12-week monitored
ART interruption. Primary outcome was time to developing a first AIDS-defining event (ADE) or death from any cause.
Analysis was by intention to treat. From 2001 to 2006, 368 patients were randomized. At baseline, mean age was 48 years,
2% were women, median CD4 count was 106/ml, mean viral load was 4.74 log10 copies/ml, and 59% had a prior AIDS
diagnosis. Median follow-up was 4.0 years in 1249 person-years of observation. There were no statistically significant
differences in the primary composite outcome of ADE or death between re-treatment options of standard versus intensive
ART (hazard ratio 1.17; CI 0.86–1.59), or between immediate retreatment initiation versus interruption before re-treatment
(hazard ratio 0.93; CI 0.68–1.30), or in the rate of non-HIV associated serious adverse events between re-treatment options.
Conclusions: We did not observe clinical benefit or harm assessed by the primary outcome in this largest and longest trial
exploring both ART interruption and intensification in advanced MDR HIV infection with poor retreatment options.
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Introduction
Despite the effectiveness of current antiretroviral (ARV)
treatment (ART) [1,2], past sequential development and avail-
ability of ARVs, significant toxicities and partially effective
combinations left many persons with multi-drug resistant (MDR)
HIV and limited re-treatment options [3,4,5,6]. In developing
countries where ART has been more recently introduced there are
increasing numbers of people with limited re-treatment options
[7]. This is due to treatment-emergent drug resistance and the lack
of or limited newer alternative ARVs that are more potent and
non-cross-resistant, yet more expensive. MDR HIV is ultimately
associated with increased risk of AIDS-associated diseases and
death [8,9].
Optimal medical management remains unclear for MDR HIV
with limited re-treatment options. Clinical management strategies
include either continuing current or alternative ARVs in an ART
regimen of up to four ARVs, intensifying ART with at least five
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and up to nine ARVs [10,11,12] chosen for expected tolerance
and activity, or interrupting ART for a period of careful clinical
observation [13,14], while maintaining or providing other relevant
prophylaxis and treatment regimens before re-initiation of ART.
Several studies have addressed treatment interruption in
patients with MDR HIV and are reviewed elsewhere [13]. While
controlled comparisons vary in context of different populations,
adequacy of re-treatment, and duration of ART interruption,
these studies have shown no consistent or lasting advantage in
terms of virological or CD4 count response. One study reported
an increase in AIDS-defining events (ADEs) after ART interrup-
tion and retreatment, in particular esophageal candidiasis, but this
study showed no difference in health-related quality of life
(HRQoL) or survival [15,16]. The use of ART interruption is
currently not supported by the US Department of Health and
Human Services (DHHS) therapeutic guidelines panel [17], and
the appearance of new ARVs such as enfuvirtide, darunavir,
etravirine, maraviroc and raltegravir offers very promising re-
treatment options for treatment failure of nucleoside and non-
nucleoside reverse transcriptase inhibitors (NRTI, NNRTI) and
protease inhibitor (PI) ARV regimens [18]. However, for the
majority of patients with treatment-emergent MDR HIV infection
in those countries with the greatest burden of HIV and resource
constraint, where conventional ART has been recently introduced,
there are very limited retreatment options.
In addition, health outcomes other than AIDS related disease
have emerged as very important indicators of burden and impact
of health in advanced HIV disease [19]. These include non-HIV
related serious adverse events (SAEs), co-morbidities such as viral
hepatitis, cardiovascular and metabolic diseases, and HRQoL
measures [20,21,22,23].
Our primary hypothesis was that ART intensification (so called
mega-ART) would result in increased clinical benefit in terms of
prolonging life and delaying the occurrence of new or recurrent
AIDS events compared to continued standard treatment. A 262
factorial study design allowed us to test a second hypothesis regarding
interruption, along with standard treatment or intensification. At the
time of study development and protocol approval, conflicting data
existed as to whether there was any benefit of interruption, for any
duration; and only uncontrolled data existed as to the possible benefit
of intensification. Our initial hypothesis regarding interruption was
that it would result in a clinical benefit, and that when combinedwith
intensification, any clinical benefit would be further increased. Our
objective therefore was to investigate these clinical management
strategies for MDR HIV infection in advanced disease with limited
ARV retreatment options.
Materials and Methods
The protocols for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1, and publication of the trial design and methods [24].
Study Design and Outcomes
OPTIMA was a randomized 262 factorial clinical trial
conducted in three countries (USA, Canada, and UK) at over
70 clinical centers. The trial was registered at http://clinicaltrials.
Figure 1. Trial profile and patient flow.
doi:10.1371/journal.pone.0014764.g001
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gov, number NCT00050089. Primary outcome was time to first
new or recurrent AIDS-defining illness or death from any cause.
Secondary outcome was time to first non-HIV related SAE.
Outcomes were reviewed by an Endpoints Review Committee
(ERC) blinded to randomization, classified either as ADEs
according to the U.S. CDC revised AIDS case definition [25]
and pre-defined criteria (OPTIMA protocol, http://www.hivnet.
ubc.ca/e/home/optima/protocol/), or as adverse events. Deaths
(by ERC) were reviewed for attribution (HIV, ART, neither or
uncertain), and all SAEs (by STB and DWC) were reviewed for
attribution (AIDS, HIV, ART, non-HIV, or not determined).
Study Ethics
The protocol was approved by independent Research Ethics
Boards at each site. The trial was performed in accordance with
the principles of Good Clinical Practice and the Declaration of
Helsinki. All volunteers signed written informed consent before
any trial related procedure.
Study Population
HIV-1 infected patients were recruited between June 2001 and
June 2006, and followed until study closure on December 31,
2007. They were eligible if the clinician was considering a change
Table 1. Baseline characteristics by treatment strategy.
Standard vs. Intensive ART ART Interruption vs. Continuation
Standard ART Intensive ART Total ART Interruption ART Continuation Total
Number of patients Randomized 192 176 368 164 175 339
Mean Age in years (SD) 48.4 (8.65) 47.6 (8.31) 48.0 (8.49) 48.7 (8.32) 48.5 (8.47) 48.6 (8.39)
Age Categories (%):
31–40 36 (19) 32 (18) 68 (18) 27 (16) 27 (15) 54 (16)
41–50 77 (40) 79 (45) 156 (42) 66 (40) 76 (43) 142 (42)
51–60 65 (34) 56 (32) 121 (33) 59 (36) 61 (35) 120 (35)
.60 14 (7) 9 (5) 23 (6) 12 (7) 11 (6) 23 (7)
Gender (%):
Male 189 (98) 172 (98) 361 (98) 160 (98) 172 (98) 332 (98)
Female 3 (2) 4 (2) 7 (2) 4 (2) 3 (2) 7 (2)
Race (%):
White 90 (47) 90 (51) 180 (49) 73 (45) 87 (50) 160 (47)
Black 80 (42) 64 (36) 144 (39) 67 (41) 71 (41) 138 (41)
Asian 2 (1) 0 (0) 2 (1) 0 (0) 1 (1) 1 (0)
Hispanic 15 (8) 21 (12) 36 (10) 21 (13) 15 (9) 36 (11)
Aboriginal 2 (1) 0 (0) 2 (1) 1 (1) 1 (1) 2 (1)
Other 3 (2) 1 (1) 4 (1) 2 (1) 0 (0) 2 (1)
Mode of Infection (%):
Blood 20 (10) 15 (9) 35 (10) 15 (9) 19 (11) 34 (10)
Heterosexual 47 (24) 39 (22) 86 (23) 41 (25) 39 (22) 80 (24)
IDU 27 (14) 25 (14) 52 (14) 24 (15) 27 (15) 51 (15)
MSM 87 (45) 88 (50) 175 (48) 76 (46) 79 (45) 155 (46)
Other 9 (5) 9 (5) 18 (5) 6 (4) 11 (6) 17 (5)
Unknown 2 (1) 0 (0) 2 (1) 2 (1) 0 (0) 2 (1)
AIDS or prior AIDS at entry (%) 107 (56) 109 (62) 216 (59) 95 (58) 105 (60) 200 (59)
Hepatitis B (HBsAg+) (%) 26 (14) 13 (7) 39 (11) 23 (14) 14 (8) 37 (11)
Hepatitis C (anti-HCV Ab+) (%) 46 (24) 34 (19) 80 (22) 39 (24) 38 (22) 77 (23)
HIV RNA copies/ml (%)
,5k 14 (7) 17 (10) 31 (8) 19 (12) 12 (7) 31 (9)
5–50k 72 (38) 58 (33) 130 (35) 56 (34) 68 (39) 124 (37)
50–100k 35 (18) 28 (16) 63 (17) 32 (20) 27 (15) 59 (17)
.100k 70 (37) 73 (41) 143 (39) 56 (34) 68 (39) 124 (37)
mean log10 (SD) 4.74 (0.62) 4.74 (0.75) 4.74 (0.68) 4.67 (0.71) 4.75 (0.66) 4.71 (0.68)
CD4 cells/ml
Mean (SD) 129 (107) 125 (106) 127 (107) 129 (106) 131(109) 130(108)
median 109 102 106 109 111 110
Virtual Phenotypic Susceptibility
Score (PSS) (mean)
1.3 1.7 1.5 1.4 1.5 1.5
doi:10.1371/journal.pone.0014764.t001
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of ART because they had twice failed NRTI based ART including
an NNRTI or a PI, or had genotypic or phenotypic evidence of
three-class (NRTI, NNRTI and PI) ARV resistance, and they
were currently receiving ART for at least three months. Other
inclusion criteria included a CD4 count #300/ml, HIV-1 plasma
viremia $5000 copies/ml (HIV-1 Amplicor Monitor 1.0 or 1.5,
Roche, Branchburg, NJ), or $2500 (Versant 3.0, Siemens,
Deerfield, IL). Exclusions were age , eighteen years, pregnancy,
nursing mothers, AIDS-defining illness within fourteen days of
screening, or likelihood of imminent death.
Study Procedures
Randomization was stratified by CD4 count at screening (above
or below 100/ml) and by study site, according to a computer-
generated randomization list, in permuted blocks of randomly
varying size by the coordinating center to re-treatment with (a)
either initial treatment interruption for an intended period of 12
weeks followed by a new ART regimen, or a change of ART
regimen without interruption, and (b) change in ART by
intensification (to $5 ARV) or standard ART (of #4 ARV). For
patients randomized to ART interruption before re-treatment, the
assigned standard or intensified ART option was not communi-
cated to the physician or the patient until the end of the planned
interruption. The ARVs in the retreatment regimens were chosen
by the treating physician according to treatment history and
expected tolerance, and by recent or screening susceptibility
testing. Low-dose ritonavir (#400 mg/day) was not counted as an
ARV. Patients were recruited, consented and followed-up in the
clinics where they received care for HIV infection and followed-up
at 6, 12, 24 and then every 12 weeks after randomization with
additional visits at 2 and 6 weeks after treatment interruption and
after re-treatment initiation. Blood samples were collected at
screening for genotypic resistance testing and virtual phenotype
(vP, VircoType, Virco, Mechelen, Belgium) and at screening and
follow-up visits for HIV-1 viral load (VL), CD4 and CD8 T
lymphocyte count and routine hematological and biochemical
blood tests. Follow-up ARV resistance testing was permitted at the
discretion of the treating physician. Incremental phenotypic
susceptibility score (PSS) from the baseline vP was calculated as
previously described [26]. Newly available ARVs including those
provided through expanded access protocols and other non-
conflicting clinical trials were permitted.
A patient was considered compliant to protocol if after
assignment to a treatment interruption it was continued for at
least 6 weeks, if they started retreatment within two weeks of their
assigned time, and they initiated retreatment with the number of
Figure 2. Time to first AIDS event or death by treatment strategy. A) Intensification versus standard antiretroviral therapy (ART); B) ART
interruption versus continuation. Time to first non HIV-related serious adverse event (SAE) by C) intensification versus standard ART; D) ART
interruption versus continuation.
doi:10.1371/journal.pone.0014764.g002
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ARVs within the assigned standard or intensive ART option.
Periods up to 30 days off ART or off the assigned number of drugs
in the standard or intensive ART regimens were allowed. Patients
were considered protocol compliant if the reason for change was
stated to be high VL, low CD4, severe adverse event or
intercurrent illness. Medication compliance was determined at
each follow-up visit using an assessment tool adopted from the
AIDS Clinical Trials Group adherence questionnaire [27]. We
also assessed HRQoL, healthcare utilization and costs, which are
described [19,28] and to be reported elsewhere.
Study Population and Sample Size Justification
The original study design [29] made the following assumptions:
1) an event rate in the standard ART group at Year 1 of 20%; with
a 25% increase annually thereafter; 2) Two-sided Type I error
(alpha) = 0.05; 3) Loss to follow-up at 3.5 years of 10%; 4) cross-
over from standard to intensive ART of 5% in year 1, increasing
10% every year thereafter; 5) cross-over from intensive to standard
ART of 20% in year 1, decreasing by 50% every year thereafter.
With 652 outcomes in 1700 subjects, a 22% relative reduction in
hazard would be detected with 93% power. During the study
sample size was revised based on observed accrual, outcome and
crossover rates, with extended accrual and follow-up periods but
no change in other assumptions, such that 261 outcomes in 390
patients would provide a study power of 75%. Also, a change was
implemented in the UK due to lack of equipoise among treating
physicians regarding ART interruption, to permit a choice of only
one of the two randomizations.
Statistical Analysis
Analyses were performed by intention to treat, according to
randomly allocated management strategy. Analyses of the primary
outcome and survival comparisons were performed using time-to-
event methods including Kaplan-Meier plots and the stratified log-
rank tests. Analyses also included interaction of treatment
assignments, length of follow-up, or calendar time of enrollment
on the primary outcome. Treatment differences were estimated by
hazard ratios using Cox proportional hazards regression. Other
Table 2. AIDS events and death by treatment strategy.
Standard
ART N (%)
Intensive
ART N (%)
Total
N (%)
ART Inter-
ruption N (%)
ART Continu-
ation N (%) Total N (%)
Number assessed 192 176 368 164 175 339
AIDS Events
Total number of AIDS events 74 73 147 47 94 141
New 53 52 105 34 69 103
Recurrent 21 21 42 13 25 38
Total number of patients having one or
more new or recurrent AIDS events
47 (24.5) 51 (29.0) 98 (26.6) 35 (21.3) 58 (33.1) 93 (27.4)
Survival
Total number of deaths 67 61 128 61 62 123
Definitely/Probably HIV-related 30 36 66 25 38 63
Definitely/Probably ART-related 1 1 2 1 1 2
Uncertain HIV or ART-related 22 18 40 26 13 39
Unlikely HIV or ART-related 14 6 20 9 10 19
Total number of patients having new or
recurrent AIDS event or death
83 (43.2) 82 (46.6) 165 (44.8) 70 (42.7) 87 (49.7) 157 (46.3)
Total follow-up time (years)* 697.9 644.9 1342.8 569.4 685.6 1255
Total at risk follow-up time (years)+ 614.8 572.8 1187.6 524.3 582.8 1107.1
Primary outcome rate per 100 person years 13.5 14.3 13.9 13.4 14.9 14.2
*Follow-up calculated as time from randomization to last assessment or death.
+Follow-up at risk calculated as time from randomization to first AIDS event or death, or last assessment.
doi:10.1371/journal.pone.0014764.t002
Table 3. First AIDS event or death by treatment strategy: stratified analysis.
Outcome Management Comparison Hazard Ratio 95% CI p-value
AIDS event or death intensification/standard; interruption/
continuation*
1.165
0.927
0.856, 1.585
0.674, 1.275
0.33
0.64
Death intensification/standard; interruption/
continuation*
1.128
1.420
0.793, 1.604
0.986, 2.045
0.50
0.06
AIDS event intensification/standard; interruption/
continuation*
1.295
0.696
0.866, 1.935
0.455, 1.065
0.21
0.09
*: Excludes UK Option patients.
doi:10.1371/journal.pone.0014764.t003
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comparisons including outcomes stratified by baseline CD4 count
(, or .100 and by quartiles ,36, 36–110, 111–196, .196/ml)
were made with standard parametric and non-parametric
statistical tests. An independent Data and Safety Monitoring
Board monitored results on an ongoing basis.
Role of Funding Source
The study funders (MRC-UK, VACSP, CIHR) reviewed and
approved the design and conduct of the trial, with external expert
reviewers who were represented on the Trial Steering Committee.
The OPTIMA Writing Committee and the OPTIMA team had
full access to the statistical report and to the study data by request
and the Writing Committee had final responsibility for the
submitted manuscript.
Results
Of the 457 patients screened, 368 patients were enrolled (VA
288, 78%; Canada 41, 11%; and UK 39, 11%), of whom 339 were
randomized to the 262 factorial and 29 were randomized to
standard vs. intensification-ART only (Figure 1). The baseline
clinical characteristics of the study population are presented in
Table 1. The study population was 98% male with a mean age of
48 (SD 8.5) years; with mean and median CD4 counts of 127 and
106/ml respectively and mean plasma HIV-1 VL of 4.74 log10
copies/ml.
The study population was heavily ARV-experienced: 96% had
taken over three NRTI (median 5, interquartile range, IQR, 4–6),
97% at least one NNRTI (median 1, IQR, 1–2), 63% at least three
PI (median 3, IQR, 2–5) and 2.5% enfuvirtide. In the retreatment
regimens, 171 (99.4%) of 172 standard-ART and 139 (91.5%) of
152 intensification-ART patients were protocol-compliant in the
number of ARVs used with a median number of ARVs of 3 in
standard and 5 in intensive ART regimens. The mean number of
active ARVs as determined by PSS was 1.3 in the standard and 1.7
in the intensive groups (p,0.03), and 1.4 in the interruption and 1.5
in the no interruption groups (P=NS). The median time to protocol
non-compliance resulting in a change in retreatment strategy was
187 (IQR 79,-) weeks for standard, versus 59 (IQR 19,155) weeks for
intensification-ART (p,0.001, log-rank test). There was no
significant difference in time to changing treatment strategy
between the ART interruption before retreatment versus immediate
ART strategy. For those assigned ART interruption, the median
duration of the interruption was 12 weeks (IQR 12–14 weeks). Use
of primary and secondary opportunistic infection prophylaxis was
high at baseline, with over 80% of patients overall taking anti-PCP,
25% taking other anti-fungal, and 45% taking other antibacterial
medications. This level of prophylaxis was maintained during the
study (in patients with CD4,200 cells/mm3) with 83%, 53%, 59%
taking anti-PCP, other anti-fungal, and antibacterial medications at
the last follow-up visit respectively.
A total of 165 (44.8%) of 368 subjects experienced a primary
outcome. This included 67 deaths without a preceding ADE, and
98 ADE of whom 61 died subsequently. Of the 165 primary
outcomes, the most common were death (40.9%), esophageal
candidiasis (18.3%), Pneumocystis jirovecii pneumonia (PCP) (8.5%),
cytomegalovirus disease (4.8%), HIV wasting syndrome (4.3%),
Mycobacterium avium complex infection (3.7%), Kaposi’s sarcoma
(2.4%), and cryptococcosis (2.4%). There was no significant
difference in the number or type ADE between re-treatment
Table 4. First AIDS event or death by treatment strategy: unstratified, 2X2 factorial analysis (includes main effects interaction).
Outcome Management Comparison Hazard Ratio 95% CI p-value*
AIDS event or death intensification/standard; interruption/
continuation
0.97
0.75
0.71, 1.33
0.53, 1.07
0.27
Death intensification/standard; interruption/
continuation
0.95
1.14
0.57, 1.56
0.7, 1.85
0.61
AIDS event intensification/standard; interruption/
continuation
0.99
0.50
0.66, 1.49
0.30, 0.84
0.25
Note: excludes UK Option patients.
*: Test for interaction.
doi:10.1371/journal.pone.0014764.t004
Table 5. First AIDS event or death by treatment strategy and by follow-up time.
Comparison Number Events or Death Hazard Ratio 95% CI p-value*
Intensification vs. standard ART (All patients)
1st year of follow-up 28 vs. 22 0.943 0.354, 1.360 0.24
2nd–7th year of follow-up 54 vs. 61 1.405 0.804, 2.455
Intensification vs. standard ART (262 factorial-excludes UK Option patients)
1st year of follow-up 26 vs. 21 0.883 0.606, 1.285 0.21
2nd–7th year of follow-up 50 vs. 60 1.372 0.772, 2.439
ART interruption vs. continuation (262 factorial-excludes UK Option patients)
1st year of follow-up 24 vs. 23 0.806 0.552, 1.178 0.33
2nd–7th year of follow-up 46 vs. 64 1.134 0.640, 2.009
*Test for heterogeneity.
doi:10.1371/journal.pone.0014764.t005
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options. The ERC adjudicated 52% of deaths to be HIV-related,
2% due to ART medication, 15% unrelated to HIV or ART, and
31% as unattributable.
Of 368 randomized to standard versus intensive retreatment,
there were respectively 83 versus 82 ADE or death outcomes
(p = 0.69, log-rank test; Figure 2A), 67 versus 61 deaths, and 47
versus 51 first ADE (Table 2). Time to the primary outcome of
ADE or death did not differ between the two groups (HR 1.17,
95% CI 0.86–1.59; p = 0.33) (Table 2). There were 339
randomized to treatment continuation versus interruption before
retreatment, and there were respectively 87 versus 70 ADE or
death outcomes (p = 0.49; log-rank Figure 2B), 62 versus 61
deaths, and 58 versus 35 ADE. Time to ADE or death did not
differ significantly between the two groups (HR 0.93, 95% CI
0.68–1.3; p = 0.64) (Table 2). ADEs and deaths were lower after
treatment interruption (Table 2), but the changes did not reach
statistical significance.
Across the four retreatment approaches of continuation +
standard, continuation + intensification, interruption + standard,
interruption + intensification in 339 subjects there were respec-
tively 46, 41, 35 and 35 ADE or death outcomes, there were 35,
27, 30 and 31 deaths, and there were 30, 28, 16 and 19 first ADE.
There was no significant difference in the time to ADE or death
across the four treatment options (p = 0.87, log-rank test).
Significantly more patients with baseline CD4 #100/ml had a
new or recurrent ADE with continuation (38 (46.3%)) compared
to with interruption (23 (30.7%), p= 0.04). In the lowest baseline
CD4 quartile (, 36/ml) more deaths occurred with intensification
than standard ART retreatment (34 (70.8%) versus 23 (48.9%),
p = 0.03), and more had ADE or death (39 (81.3%) versus 26
(55.3%), p = 0.007). Finally, tests of main effect interactions
demonstrated no statistical significance in AIDS events or death
when treatment assignment, length of follow-up, or calendar time
of enrollment were considered (Tables 3, 4, 5, 6).
185 of 368 (50%) patients developed 481 non HIV-related
SAEs. There was no significant difference in number or time to
first non HIV-related SAE between standard vs. intensive ART
retreatment (log-rank p= 0.92, HR 1.008, 95%CI 0.75–1.35), or
between interruption versus continuation (log rank p= 0.68, HR
1.08, 95%CI 0.8–1.46) (Figures 2C and D).
Expected changes in CD4 lymphocyte counts and plasma HIV
viral load were observed (Figure 3); viremia measures and CD4
appeared to at least recover over time after interruption and re-
treatment. After week 24, there was no significant difference in
CD4 count or viremia between groups.
Discussion
There are randomized control trials in retreatment of
treatment-failing or drug-resistant HIV infection with unpromising
retreatment options, which evaluate new ARVs [30] or treatment
intensification and treatment interruption of varied duration
[13,14,15,16]. New ARV drug classes with low cross-resistance
are rightly favoured when available, and there is evidence that the
more ‘active’ ARVs used the better the outcome. Treatment
intensification with familiar drug classes is expensive and seen as
desperate, while treatment interruption has not been shown to be
beneficial. OPTIMA was challenged by slow accrual due to a
small number of patients with MDR-HIV who were willing to
accept allocation to retreatment options that could be obtained
without joining a trial, by clinical heteropoise - a lack of equipoise
which varies in degree and direction - with respect to
intensification and interruption, and by new ARV development
trials which offered a chance of perceptibly favorable retreatment
ARV regimens. This was further demonstrated in the UK, where
some treating physicians did not feel it was appropriate to consider
both strategies in OPTIMA and so randomization was split to
offer patients a choice. In addition, there was competition in the
UK for enrolling patients with MDR-HIV in trials of newer agents
that were perceived to be likely more potent than the strategies
offered in OPTIMA. Nevertheless, OPTIMA is the largest and
longest controlled trial of ART management options in MDR-
HIV with advanced HIV immune deficiency and poor retreat-
ment options, for both AIDS and non-HIV SAE and HRQoL
outcomes. Although randomized management allocation in this
trial was not blinded to patients or healthcare providers, the
rigorous conduct, the clinical nature of outcomes and complete-
ness of follow-up distinguish this trial from ARV activity trials
measuring surrogate markers in smaller and shorter trials.
Although no significant advantage or disadvantage to any of the
retreatment options was seen in over 1000 person-years of
observation, confidence limits here may include a clinically
significant effect that is not reflected in the simple outcome rates.
For example, the data are consistent with a possible 14% decrease
or 59% increase in death or ADE with treatment intensification;
and approximately a 32% decline or 30% increase in death or
ADE with treatment interruption. Unlike other reports, there was
no excess risk of ADE with ART interruption in patients with the
highest expected risk defined by lowest baseline CD4 counts. For
example, Lawrence et al. reported on a controlled trial of 16-week
treatment interruption, which showed an excess of treatment-
responsive esophageal candidiasis, but no difference in HRQoL or
in survival [15,16]. This difference in outcome could be related to
a higher proportion of patients in the OPTIMA trial receiving
anti-infective prophylaxis (87% for PCP and 53% for candidiasis
with a CD4 count,200 per ml). Additional analysis was suggestive
of a trend toward increased mortality following resumption of
therapy in patients undergoing treatment interruption; while not
statistically significant, this trend might provide some clinically
important insight in therapeutic modalities.
No other trials of retreatment intensification evaluate clinical
outcomes, and there is a valid concern for toxicity, tolerance and
Table 6. First AIDS event or death by treatment strategy and
by calendar time.
Comparison
Number
Events or
Death
Hazard
Ratio 95% CI p-value*
Intensification vs. standard ART (All patients)
15Jun01–31Dec03 25 vs. 27 0.949 0.550, 1.636 0.76
01Jan04–31Dec06 42 vs. 41 0.997 0.650, 1.529
01Jan07–31Dec07 15 vs. 14 1.319 0.637, 2.734
Intensification vs. standard ART (262 factorial-excludes UK Option patients)
15Jun01–31Dec03 25 vs. 26 1.006 0.581, 1.743 0.86
01Jan04–31Dec06 37 vs. 41 0.924 0.593, 1.445
01Jan07–31Dec07 14 vs. 14 1.174 0.560, 2.462
ART interruption vs. continuation (262 factorial-excludesUKOptionpatients)
15Jun01–31Dec03 27 vs. 24 1.057 0.610, 1.834 0.18
01Jan04–31Dec06 34 vs. 44 0.923 0.590, 1.448
01Jan07–31Dec07 9 vs. 19 0.437 0.198, 0.965
*Test for heterogeneity.
doi:10.1371/journal.pone.0014764.t006
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cost as well as efficacy of intensified ART. OPTIMA identified no
significant overall benefit in health outcomes or harm in excess
non-HIV SAEs or drug intolerance. However, maintenance of
intensification was much less than a standard ART retreatment
option so that no difference in cumulative additive or antagonistic
effects from additional medications in MEGA-ART were seen.
In an ART era of new and very promising retreatment options
of new class ARVs and combinations, what instruction may be
taken from these trials of retreatment management options for
HIV treatment failure? In the developing world, the greatest
burden of HIV and the greatest healthcare resource constraints
co-exist. Conventional ARV roll-outs for the many untreated are
still expanding and leave little room to allocate added resources for
the inevitable adherence- and intolerance-driven failures of ART
and treatment-emergent MDR-HIV. In clinical practice, treat-
ment interruption is a common occurrence. A recently completed
trial in Uganda exploring short, intermittent HIV treatment
interruption in a healthier population found that 7 days on and 7
days off ARVs resulted in more virologic failures compared to 7
day or 5 day continuous treatment cycles which yielded
comparable results [31]. Although the treatment population,
strategy and measured outcome from this study is not directly
comparable to the MDR patients in OPTIMA, it demonstrates
that some forms of ARV interruption strategy may be used as a
compromise in the right clinical context.
OPTIMA suggests that in some settings of ART failure with
limited prospects for re-treatment, individualization of retreatment
for interruption or intensification with conventional ARVs may be
considered, particularly with good clinical follow-up and manage-
ment of opportunistic infection risk. Such decisions should
carefully weigh both potential benefits and harms. As trials of
this nature in these types of settings are unlikely in the future, a
pooling of existing trial datasets may offer the best opportunity to
identify principles and particular populations which may gain or
lose most in ARV retreatment choices after failure of ART, MDR-
HIV and limited retreatment options.
Supporting Information
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0014764.s001 (0.16 MB
RTF)
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0014764.s002 (1.06 MB
PDF)
Figure 3. Immunological and virological changes over time by treatment strategy. A) CD4 count change, intensification vs. standard
antiretroviral therapy (ART); B) CD4 count change, ART interruption vs. continuation; C) HIV-1 viral load change, intensification vs. standard ART; D)
HIV-1 viral load change, ART interruption vs. continuous.
doi:10.1371/journal.pone.0014764.g003
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